PROLOR Biotech (PBTH) Reports Positive Data from Factor VIIa-CTP in Hemophilic Mice
Up)
PROLOR Biotech, Inc. (AMEX: PBTH), reports positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice. The study was designed to measure the potential increase in survival rates, thrombin levels and in vivo recovery of Factor VIIa-CTP when compared with commercially available recombinant Factor VIIa. In vivo recovery is a pharmacokinetic parameter used by researchers that compares actual clotting activity post-dosing to anticipated clotting activity. PROLOR previously announced positive results in an earlier comparative study that measured the increase in half-life and clotting activity of Factor VIIa-CTP compared to commercially available Factor VIIa.
The new study showed that compared to commercially available Factor VIIa, hemophilic mice receiving PROLOR's Factor VIIa-CTP demonstrated:
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The new study showed that compared to commercially available Factor VIIa, hemophilic mice receiving PROLOR's Factor VIIa-CTP demonstrated:
- A superior survival rate over a longer time period following a bleeding challenge.
- Superior and longer-lasting generation of thrombin, a key pro-clotting enzyme.
- Significantly higher in vivo recovery.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Medivation (MDVN) Submits NDA for Enzalutamide to U.S. FDA
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
